A Randomized, Double Blind Third Party Open Placebo-Controlled Exploratory Study To Evaluate The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2015
At a glance
- Drugs PF 5089771 (Primary)
- Indications Pain
- Focus Therapeutic Use
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Feb 2013 Planned End Date changed from 1 Dec 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 27 Jan 2013 New trial record